Abstract
The discovery of new biomarkers is a rapidly advancing area in cancer biology. The challenge of biomarker development for broad clinical use requires the translation of lab-based knowledge into clinical practice. The Long Interspersed Nuclear Elements-1 (LINE-1s or L1 elements) are active members of an autonomous family of non-LTR retrotransposons and occupy nearly 17% of the human genome. There is strong experimental evidence that the global hypomethylation of genomic DNA in cancer cells results in the activation of L1s and their expression is detectable at genome, transcriptome and proteome levels in human cancer cells. Thus, human L1s constitute a potential marker for cancer cells. In this review we have attempted to scrutinize L1 expression profiles in clinical cancer studies by undertaking a comprehensive systematic analysis of papers published in the field so far with a view to providing a more complete picture of the detection methods used, improvements achieved and potential future directions. Ultimately, we will try to evaluate the potential of L1s as a molecular marker in cancer detection.
Keywords: Human, LINE-1, L1 element, retrotransposon, cancer, biomarker, detection, screening techniques, genome, remnants, reverse transcriptase, junk DNA, polymorphism, mutagenesis, anticancer therapy
Current Molecular Medicine
Title: The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Volume: 11 Issue: 4
Author(s): O. Piskareva, W. Lackington, D. Lemass, C. Hendrick, P. Doolan and N. Barron
Affiliation:
Keywords: Human, LINE-1, L1 element, retrotransposon, cancer, biomarker, detection, screening techniques, genome, remnants, reverse transcriptase, junk DNA, polymorphism, mutagenesis, anticancer therapy
Abstract: The discovery of new biomarkers is a rapidly advancing area in cancer biology. The challenge of biomarker development for broad clinical use requires the translation of lab-based knowledge into clinical practice. The Long Interspersed Nuclear Elements-1 (LINE-1s or L1 elements) are active members of an autonomous family of non-LTR retrotransposons and occupy nearly 17% of the human genome. There is strong experimental evidence that the global hypomethylation of genomic DNA in cancer cells results in the activation of L1s and their expression is detectable at genome, transcriptome and proteome levels in human cancer cells. Thus, human L1s constitute a potential marker for cancer cells. In this review we have attempted to scrutinize L1 expression profiles in clinical cancer studies by undertaking a comprehensive systematic analysis of papers published in the field so far with a view to providing a more complete picture of the detection methods used, improvements achieved and potential future directions. Ultimately, we will try to evaluate the potential of L1s as a molecular marker in cancer detection.
Export Options
About this article
Cite this article as:
Piskareva O., Lackington W., Lemass D., Hendrick C., Doolan P. and Barron N., The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions, Current Molecular Medicine 2011; 11 (4) . https://dx.doi.org/10.2174/156652411795677954
DOI https://dx.doi.org/10.2174/156652411795677954 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HGF/MET Signaling in Ovarian Cancer
Current Molecular Medicine Nanomedicines for Intravesical Chemotherapy in Bladder Cancer
Current Pharmaceutical Design Further Vitamin D Analogs
Current Vascular Pharmacology Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Phosphorothioate-Stimulated Uptake of siRNA by Mammalian Cells: A Novel Route for Delivery
Current Topics in Medicinal Chemistry Prophylaxis of Cancer
Current Cancer Therapy Reviews Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry NCRNA Combined Therapy as Future Treatment Option for Cancer
Current Pharmaceutical Design FDG-PET Imaging in Large Vessel Vasculitis and Polymyalgia Rheumatica: A Personal View
Current Immunology Reviews (Discontinued) Discovery of New Inhibitors of Urease Enzyme: A Study Using STD-NMR Spectroscopy
Letters in Drug Design & Discovery Cancer Risk and Nullity of Glutathione-S-Transferase Mu and Theta 1 in Occupational Pesticide Workers
Current Pharmaceutical Biotechnology Cyclooxygenase as a Target for Colorectal Cancer Chemoprevention
Current Drug Targets Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Current Vascular Pharmacology Exploring the Potential of NO-Independent Stimulators and Activators of Soluble Guanylate Cyclase for the Medical Treatment of Erectile Dysfunction
Current Pharmaceutical Design Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Expression of Specificity Protein Transcription Factors in Pancreatic Cancer and their Association in Prognosis and Therapy
Current Medicinal Chemistry The Adenosine A2b Receptor: Its Role in Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets The CLCA Gene Family A Novel Family of Putative Chloride Channels
Current Genomics Targeted Therapies in Gynecologic Cancers
Current Cancer Drug Targets